Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy - Test2 - elhamkhani - TriplyDB

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy

http://www.wikidata.org/entity/Q28269627

about

Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis Epigenetic modulators as therapeutic targets in prostate cancer Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation Targeting the Bromome: are we there yet?Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals.Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.Epigenetic Strategies to Boost Cancer Immunotherapies.Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.The Role of Histone Protein Modifications and Mutations in Histone Modifiers in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.Selective targeting of Bromodomains of the Bromodomain-PHD Fingers family impairs osteoclast differentiation.Progress in the Development of non-BET Bromodomain Chemical Probes.Epigenomic regulation of oncogenesis by chromatin remodeling.Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma Epigenetic regulation of cardiac fibrosis.Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire.Selective targeting of epigenetic reader domains.Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology.Bromodomain inhibitors and cancer therapy: From structures to applications.Allosteric regulation of epigenetic modifying enzymes.Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation.BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression.Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.Protein dynamics and structural waters in bromodomains.Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.Chemical probes and inhibitors of bromodomains outside the BET family.Peptidomimetic blockade of MYB in acute myeloid leukemia.CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of Plasmodium falciparum invasion.Cation-π interactions in CREBBP bromodomain inhibition: an electrostatic model for small-molecule binding affinity and selectivity.Beyond the BET Family: Targeting CBP/p300 with 4-Acyl Pyrroles.Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.

P2860

Q27644535-905BE895-7F50-4E5A-94BE-09E746845F23 Q27644651-26F1310B-630E-4641-9CB6-085C47CAE9CF Q27728041-F8039E36-57CA-4579-A78B-62287515CB91 Q28071912-D0CA1C22-DDD4-476C-9A09-7C2E325FAF91 Q28076086-49CE6F05-4D68-454C-9CF4-237356BE1980 Q28818241-E12AE6A6-9F11-49F1-9B0D-394A5E826ED5 Q30489777-41951CDE-C326-4C05-8B55-E317AACB59FB Q33633254-7B55EFF8-7A17-4AFE-AA69-36E889F72F72 Q33791305-4C74F63C-4B43-4B33-97FC-E7227E79179C Q33838340-12424FDC-3786-4269-9375-AD68F6236B27 Q36012341-3BC1BFE7-A112-4373-8E24-60BA77565F34 Q37223691-9E111823-376C-45EF-BC80-277D126CD4F4 Q37334404-AD6CB9E3-69D0-47B6-A168-24AC6AC9A9B5 Q37629537-B9D2A69A-B15A-4E0B-B80A-388D9C69428A Q37633585-5F3B9A0E-2E31-473B-978F-39EAA5FFA342 Q38604141-82369D92-D7F3-40D0-8BA2-B9DE95FD0AC5 Q38691377-4F878E99-3143-4C5B-AA50-35CA23F32618 Q38709544-4251C97B-918E-4AFC-ADA5-0396E5644329 Q38729035-8F6DACF5-1FD8-47DA-829C-C64A06E5473E Q38733315-656490F9-ACB9-4D67-8452-A275E43392F1 Q38741165-FA57B71A-D6A2-405B-88FD-9054661D2C6C Q38744593-8B02D1AE-A67C-494A-8FB9-2A3835A59E65 Q38748150-AE4E90EA-4DB3-47A1-8ED1-7D5A8618D64A Q38837561-AC133380-7F4D-4131-9378-1C872F1DDC8C Q39027056-22B0AAB3-8E1C-4B09-B932-86CD228C1CE0 Q39423283-9BE553D3-886B-4E79-8791-0BF12531EE47 Q39423291-FD690304-36E2-4416-B703-D2BF1A31E6E5 Q39737405-1B401F76-6662-4EAC-A458-067B8F153552 Q41534994-D904FF93-DA6E-40A7-9A75-F2ED8D2B79E7 Q41895213-57716EB6-D223-4EF8-844E-5A35E9FBFBA1 Q42320410-8B461390-7643-4AA8-A59E-4B6303CA0540 Q42513461-E15A743D-9871-4C31-A8F7-322B39914B24 Q44452823-692DC8F4-BF25-47CF-B2F9-FE9669A3CF76 Q46985603-FF78DA16-28DD-43A2-8FA6-5BA010389C5B Q47128083-B35E868C-92FD-4BAD-9FBC-EE075179C21B Q47215625-73E00053-DBAB-4870-B048-52DA4AA0681D Q48014614-1E5B87A4-F25F-400B-AEDF-94E8739CDD0F Q48245176-C9450500-5232-40FB-824B-5A22EF2AB392 Q48307308-6D5E8DD5-908F-45E7-B114-73EAB8BAC730 Q49592738-F61333AA-067E-4132-A9DD-F2035E7EA409

P2860

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy

http://www.wikidata.org/entity/Q28269627

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@ast

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@en

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@en-gb

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@nl

type

label

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@ast

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@en

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@en-gb

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@nl

prefLabel

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@ast

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@en

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@en-gb

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@nl

P1433

Q28269627-0C19B1FA-A62A-43B9-9F7C-8B9CA7A4FCAF

P1476

Q28269627-48ADCE8F-2585-438B-B631-6B5341A838E5

P2093

Q28269627-02E7868D-27AB-4883-AA52-ADDEB471899D

Q28269627-053EEB1A-6CF6-4363-B72E-81914054BAD9

Q28269627-07CE0006-2A4E-4066-81A6-A3EB8B06A12F

Q28269627-12BD41FD-7583-472F-9FB9-A3322A88E26F

Q28269627-27CB207B-D4A5-4FE5-A417-5FAF9FD6C604

Q28269627-33D7FD91-8ECC-4F9B-9486-1FF5CAC67155

Q28269627-36D6230A-8E4E-4195-9DCC-7630CBB132C1

Q28269627-37299571-BF7E-4D0A-AB6D-F6D97373FDDB

Q28269627-397B4049-1795-42E9-9DFF-2B7D9237B832

Q28269627-4E67C40D-E765-4809-97B2-1D4D2F9C178F

P2860

Q28269627-072F5754-8564-437A-9674-7FAD773FB21D

Q28269627-0BC7092F-A53B-4AAA-99F0-58AC52E07DA3

Q28269627-15782097-79EB-4A5F-83AB-AE77998D942C

Q28269627-174A41F7-3B80-4FC8-A383-B81B0F347BB5

Q28269627-1C2459A5-A6AC-40C4-8719-373B12916EF2

Q28269627-1C5DADC5-875C-4E8C-8681-C392ABF32FB5

Q28269627-21496B27-2B8C-4898-AC20-DAE878073AA0

Q28269627-250ED4E7-BF54-440B-9B8E-1FFA00BFFC4B

Q28269627-290BB045-B8B6-424F-BBA4-058F7FD13BE9

Q28269627-3266737F-28B9-4253-B7F7-650D2A7FFF80

P304

Q28269627-C31F5FCC-70DC-4026-B92A-1691F17C7EFD

P31

Q28269627-2310F8B8-F6D9-4D6C-8F0D-9AE7CECC3EEF

P3181

Q28269627-E12CDD09-B30D-45F8-878C-815C44AB0368

P356

Q28269627-89862E7F-58A1-4C6C-9C84-59FA4EE819E0

P407

Q28269627-4B6D6BC0-E8E5-418F-9A8D-C37780E801B8

P433

Q28269627-A2B1C876-4A00-4E60-A3D5-63EF74AA5F30

P478

Q28269627-BC923947-E4BF-4386-A806-FDF60BE2AAB1

P50

Q28269627-0E940CD1-A3FD-4D45-A2F2-84CF41F2FA39

Q28269627-190763B2-88E0-4099-99CB-70E2F7351011

Q28269627-5ECF038A-352B-4780-8B3C-991ED8701BE2

Q28269627-72875818-D115-48FF-BA94-68F86C78FE04

Q28269627-8B0551A8-D4AC-4CA4-872C-85B220C25F6E

Q28269627-CC77130D-23E3-4844-85B7-CE1F50B59FC2

Q28269627-EE757364-66D3-47DE-884E-A77E80F7C292

P577

Q28269627-BE693546-D2A8-4A85-A87C-B7FAF31B54D8

P698

Q28269627-8460E1B0-7258-4AB5-90A7-8FEEAC85DC05

P921

Q28269627-4DB38C04-513C-4501-9DD4-6B1ADFC6830B

P932

Q28269627-24818F63-B1BB-4EFA-B62C-859FD5251AB1

P3181

P356

0008-5472.CAN-15-0236

P1433

Cancer Research

P1476

Generation of a Selective Smal ...... omodomain for Leukemia Therapy

@en

P2093

Alison O'Mahony

http://www.w3.org/2001/XMLSchema#string

Angeliki Thanasopoulou

http://www.w3.org/2001/XMLSchema#string

Anthony Tumber

http://www.w3.org/2001/XMLSchema#string

Chas Bountra

http://www.w3.org/2001/XMLSchema#string

Christopher Wells

http://www.w3.org/2001/XMLSchema#string

Clarence Yapp

http://www.w3.org/2001/XMLSchema#string

Danette L Daniels

http://www.w3.org/2001/XMLSchema#string

Dave Lugo

http://www.w3.org/2001/XMLSchema#string

Duncan Hay

http://www.w3.org/2001/XMLSchema#string

Julia Meier

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity

Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells

Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation

Suppression of inflammation by a synthetic histone mimic

A Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in Cardiomyocytes

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation

P304

5106-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3017894

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-15-0236

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

Tony Kouzarides

Panagis Filippakopoulos

Susanne Müller

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26552700

http://www.w3.org/2001/XMLSchema#string

P921

P932

4948672

http://www.w3.org/2001/XMLSchema#string